Ultime notizie per Nutriband (NASDAQ:NTRB) Azioni

Nutriband

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Nutriband Inc

In the current session, the stock is trading at $116.97, after a 1.36% increase. Over the past month, Duke Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) stock increased by 0.51%, and in the past year, by 16.74%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1750716075_0.png" alt="Past Year Chart" />

<h3>Duke Energy P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 19.21 in the Electric Utilities industry, Duke Energy Inc. has a lower P/E ratio of 19.15. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750716075_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

News

Intraday Update

Markets

A Look Into Duke Energy Inc's Price Over Earnings

Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $55.0, a high estimate of $68.00, and a low estimate of $42.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.22%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750716054_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Moelis's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>James Yaro</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$63.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$42.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Moelis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moelis compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Moelis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Moelis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Moelis analyst ratings.</a>
<h2>All You Need to Know About Moelis</h2>
Moelis &amp; Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
<h3>Moelis: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Moelis's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 40.97%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.4%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Moelis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 10.86%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.89%, the company showcases effective utilization of assets.
Debt Management: Moelis's debt-to-equity ratio is below the industry average at 0.45, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

6 Analysts Assess Moelis: What You Need To Know

American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has outperformed the market over the past 20 years by 4.08% on an annualized basis producing an average annual return of 12.5%. Currently, American Tower has a market capitalization of $103.75 billion. 
Buying $100 In AMT: If an investor had bought $100 of AMT stock 20 years ago, it would be worth $1,065.53 today based on a price of $221.63 for AMT at the time of writing.
<h3>American Tower's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750715112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In American Tower 20 Years Ago Would Be Worth Today

Shares of AI cloud infrastructure provider CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) fell 5.39% to $173.68 on Monday, reversing some of last week's sharp gains. The decline comes amid broad market volatility, driven by escalating tensions in the Middle East that are beginning to rattle global trade and energy flows.
What To Know: The sell-off in CoreWeave likely reflects profit-taking after <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45984765/coreweave-crwv-stock-hits-new-all-time-high-today-whats-going-on">last week&#8217;s rally</a> to a record high of $187. Despite no major company news, CoreWeave surged on continued AI enthusiasm and a strong fundamental backdrop, including a 420% revenue jump and a $25.9 billion backlog.
Still, a recent analyst <a href="https://www.benzinga.com/quote/CRWV/analyst-ratings">downgrade</a> from Bank of America citing valuation concerns, added pressure.
Read Also: <a href="https://www.benzinga.com/news/25/06/46055156/sp500-oil-crisis-performance-iran">War, Oil, And S&amp;P 500: Here&#8217;s How The Stock Market Behaves In Energy Crises</a>
Market Update: The market has been extremely volatile on Monday as maritime traffic data from key chokepoints such as the Strait of Hormuz and the Suez Canal shows <a href="https://www.benzinga.com/news/politics/25/06/46047021/iran-threatens-strait-of-hormuz-after-us-bombs-its-nuclear-sites-shipping-traffic-plunges">steep declines</a> across crude oil tankers, container ships and bulk carriers, suggesting rising geopolitical risk and potential supply chain disruptions.
Notably, container traffic has plunged over 21% through Hormuz and nearly 31% through Suez, pointing to both rerouting and weakened demand, especially from industrial powerhouses like China.
With Iran&#8217;s parliament voting to potentially close the Strait of Hormuz, markets are bracing for further volatility, leaving high-growth names like CoreWeave potentially exposed. According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CRWV has a 52-week high of $187 and a 52-week low of $33.52.
Read Also: <a href="https://www.benzinga.com/news/25/06/46055156/sp500-oil-crisis-performance-iran">War, Oil, And S&amp;P 500: Here&#8217;s How The Stock Market Behaves In Energy Crises</a>
<h1 class="wp-block-heading">How To Buy CRWV Stock</h1>
By now, you're likely curious about how to participate in the market for CoreWeave, be it to purchase shares or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option or sell a call option at a strike price above where shares are currently trading — either way, it allows you to profit from the share price decline.
Image: Shutterstock

Global

Tech

CRWV

CoreWeave (CRWV) Stock Falls Sharply Monday: What Happened?

General

TLSI

TriSalus Life Sciences Initiates Exchange Offer And Consent Solicitation Relating To Series A Convertible Preferred Stock To Streamline Capital Structure

Buybacks

BLFY

Blue Foundry Bancorp Authorizes The Adoption Of Its Sixth Stock Repurchase Program To Repurchase Up To 1,082,533 Shares Of The Company's Common Stock, Which Is ~5% Of Its Outstanding Common Stock

Essential Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) has outperformed the market over the past 5 years by 1.56% on an annualized basis producing an average annual return of 16.43%. Currently, Essential Properties has a market capitalization of $6.49 billion. 
Buying $100 In EPRT: If an investor had bought $100 of EPRT stock 5 years ago, it would be worth $206.45 today based on a price of $32.86 for EPRT at the time of writing.
<h3>Essential Properties's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750714223_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EPRT

Here's How Much You Would Have Made Owning Essential Properties Stock In The Last 5 Years

<a href="https://www.bloomberg.com/news/articles/2025-06-23/tesla-robotaxi-videos-show-speeding-driving-into-wrong-lane?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-23/tesla-robotaxi-videos-show-speeding-driving-into-wrong-lane?embedded-checkout=true</a>

TSLA

'Tesla Robotaxi Issues Draw Scrutiny From Auto Safety Regulator'- Bloomberg

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.59% on an annualized basis producing an average annual return of 12.01%. Currently, Gilead Sciences has a market capitalization of $132.09 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,798.39 today based on a price of $106.19 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750713324_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GILD

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-06-23/starbucks-rises-on-report-it-s-mulling-sale-of-china-business">https://www.bloomberg.com/news/articles/2025-06-23/starbucks-rises-on-report-it-s-mulling-sale-of-china-business</a>

SBUX

'Starbucks Rises on Report It's Mulling Sale of China Business'- Bloomberg

DATROWAY Approved In The U.S. As First TROP2 Directed Therapy For Patients With Previously Treated Advanced EGFR-mutated Non-Small Cell Lung Cancer; DATROWAY Is Being Jointly Developed And Commercialized By Daiichi Sankyo And AstraZeneca

WIIM

CHWY

CHWY stock has given up its prior loss. Chewy shares were trading lower after the company announced a public offering of Class A common stock by a selling stockholder and a concurrent share repurchase.

Contracts

Oceaneering International Awarded U.S. Navy Contract; The Contract Value Is ~ $33M If All Options Are Exercised Over The Five-Year Ordering Period

<h3>Gainers</h3>
<ul>
<li>GIBO Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) shares moved upwards by 17.8% to $0.67 during Monday's after-market session. The company's market cap stands at $681.8 million. </li>
<li>TEN Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) stock rose 6.96% to $0.47. The company's market cap stands at $12.5 million. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) shares moved upwards by 6.13% to $2.77. The company's market cap stands at $4.1 million. </li>
<li>Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) stock rose 4.4% to $3.79. The company's market cap stands at $1.1 billion. </li>
<li>DHI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHX#NYSE">DHX</a>) shares rose 4.08% to $2.8. The company's market cap stands at $124.8 million. </li>
<li>Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) shares increased by 4.04% to $32.89. The market value of their outstanding shares is at $1.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>E W Scripps (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) shares declined by 7.2% to $2.85 during Monday's after-market session. The company's market cap stands at $273.1 million. </li>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock decreased by 6.43% to $0.16. The company's market cap stands at $2.2 million. </li>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) stock declined by 5.62% to $0.77. The market value of their outstanding shares is at $8.6 million. </li>
<li>Grupo Televisa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TV#NYSE">TV</a>) stock declined by 4.65% to $2.26. The company's market cap stands at $2.4 billion. </li>
<li>Beasley Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) stock decreased by 3.68% to $4.19. The market value of their outstanding shares is at $8.3 million. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares decreased by 3.61% to $0.67. The company's market cap stands at $8.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BAOS

BBGI

BLMZ

GIBO

MITQ

TBLA

XHLD

12 Communication Services Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock moved upwards by 53.8% to $3.86 during Monday's after-market session. The company's market cap stands at $111.3 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock increased by 42.3% to $1.02. The market value of their outstanding shares is at $12.5 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares moved upwards by 22.11% to $11.65. The market value of their outstanding shares is at $105.5 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) stock moved upwards by 14.96% to $3.15. The company's market cap stands at $4.2 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) stock rose 9.82% to $0.28. The market value of their outstanding shares is at $15.8 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 9.22% to $9.0. The market value of their outstanding shares is at $5.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock fell 19.3% to $1.3 during Monday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock decreased by 6.88% to $0.28. The company's market cap stands at $1.1 million. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock declined by 6.87% to $1.9. The market value of their outstanding shares is at $75.5 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares declined by 5.87% to $0.43. The market value of their outstanding shares is at $18.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares decreased by 5.36% to $0.22. The company's market cap stands at $12.6 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock declined by 5.29% to $0.86. The company's market cap stands at $27.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

CARM

CERO

CGTX

FEMY

HURA

IBIO

NKTR

NUWE

XBIO

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>CPI Aerostructures (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVU#AMEX">CVU</a>) stock rose 6.7% to $3.33 during Monday's after-market session. The market value of their outstanding shares is at $40.3 million. </li>
<li>Euroholdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHLD#NASDAQ">EHLD</a>) stock rose 6.4% to $8.14. The company's market cap stands at $18.6 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares increased by 6.16% to $3.1. The company's market cap stands at $105.4 million. </li>
<li>Huachen AI Parking Mgmt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) shares moved upwards by 6.0% to $1.06. The market value of their outstanding shares is at $33.1 million. </li>
<li>Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) stock moved upwards by 5.44% to $1.72. The company's market cap stands at $90.0 million. </li>
<li>WF Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) stock increased by 5.22% to $6.85. The market value of their outstanding shares is at $177.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) stock decreased by 10.4% to $6.0 during Monday's after-market session. The market value of their outstanding shares is at $14.6 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares decreased by 10.38% to $0.26. The company's market cap stands at $5.6 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock fell 10.23% to $2.81. The market value of their outstanding shares is at $63.9 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares decreased by 9.94% to $0.95. The company's market cap stands at $81.8 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares fell 9.65% to $0.27. The company's market cap stands at $11.6 million. </li>
<li>Zooz Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZOOZ#NASDAQ">ZOOZ</a>) stock decreased by 6.36% to $0.72. The company's market cap stands at $9.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BAER

EHLD

HCAI

LGCL

NEOV

RBNE

RYDE

ZBAI

ZOOZ

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Trio-Tech Intl (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TRT#AMEX">TRT</a>) shares moved upwards by 13.9% to $6.06 during Monday's after-market session. The market value of their outstanding shares is at $22.9 million. </li>
<li>Creative Global Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) stock moved upwards by 8.54% to $1.27. The market value of their outstanding shares is at $31.0 million. </li>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) stock increased by 7.29% to $1.25. The company's market cap stands at $19.7 million. </li>
<li>Maxeon Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) shares increased by 6.1% to $2.78. The market value of their outstanding shares is at $47.9 million. </li>
<li>BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) stock rose 5.96% to $54.0. The market value of their outstanding shares is at $175.6 million. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock increased by 5.86% to $0.73. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) shares decreased by 14.1% to $1.89 during Monday's after-market session. The market value of their outstanding shares is at $59.1 million. </li>
<li>Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) shares declined by 5.39% to $1.58. The market value of their outstanding shares is at $119.5 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock fell 5.09% to $1.12. The company's market cap stands at $13.0 million. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares fell 5.01% to $3.8. The company's market cap stands at $3.4 million. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) stock declined by 4.83% to $2.07. The company's market cap stands at $1.5 billion. </li>
<li>Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) shares decreased by 4.77% to $1.8. The company's market cap stands at $39.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AWRE

BKTI

CGTL

GREE

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MOVE

Next Technology Holding Inc. - Ordinary Shares

NXTT

SONM

SQNS

TAOP

XTKG

12 Information Technology Stocks Moving In Monday's After-Market Session

TuHURA Biosciences And Kineta Receive Stockholders' Approval For Proposed Merger And All Related Proposals

Analysts' ratings for Boston Beer Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $252.0, with a high estimate of $285.00 and a low estimate of $187.00. This current average has decreased by 1.79% from the previous average price target of $256.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1750712504_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Boston Beer Co is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonnie Herzog</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$187.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$279.00</td>
<td>$279.00</td>
</tr>
<tr>
<td>Sean King</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$279.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Michael Lavery</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$280.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Beer Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Boston Beer Co compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Boston Beer Co's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Boston Beer Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SAM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boston Beer Co analyst ratings.</a>
<h2>All You Need to Know About Boston Beer Co</h2>
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.
<h3>Financial Insights: Boston Beer Co</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Boston Beer Co's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.53% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.
Net Margin: Boston Beer Co's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Boston Beer Co's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Boston Beer Co's ROA stands out, surpassing industry averages. With an impressive ROA of 1.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Boston Beer Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Boston Beer Co Through The Eyes Of 5 Analysts

Analysts' ratings for GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $216.25, a high estimate of $240.00, and a low estimate of $180.00. This current average represents a 3.57% decrease from the previous average price target of $224.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1750712493_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of GoDaddy among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Alexei Gogolev</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$234.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Elizabeth Elliott</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$206.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to GoDaddy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GoDaddy compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for GoDaddy's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into GoDaddy's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GDDY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GoDaddy analyst ratings.</a>
<h2>All You Need to Know About GoDaddy</h2>
GoDaddy provides domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
<h3>Understanding the Numbers: GoDaddy's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: GoDaddy displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 7.74%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: GoDaddy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 49.23%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): GoDaddy's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.73% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: GoDaddy's debt-to-equity ratio stands notably higher than the industry average, reaching 19.46. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GDDY

Beyond The Numbers: 8 Analysts Discuss GoDaddy Stock

Press Releases

UPDATE – Nutriband Signs Associate Partnership with Charlotte FC

Legal

Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology

Nutriband Inc (NASDAQ: NTRB) Solution To Fentanyl Abuse Could Translate To $200 Million In Peak Revenue

Nutriband CEO Publishes Letter to Shareholders

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.

Earnings

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference

Health Care

Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Comments

Nutriband

Notizie

Ultime notizie per Nutriband (NASDAQ:NTRB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO